Date: 2016-12-07
Type of information: Nomination
Compound: president, chief executive officer
Company: Tmunity Therapeutics (USA - PA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 7, 2016, Tmunity Therapeutics announced that it has named Usman “Oz” Azam to the new post of president and chief executive officer. Dr. Azam will help to deliver the company’s vision to discover, develop, manufacture and market treatments that unleash the immunological potential of T cells to treat a wide variety of diseases. A veteran life sciences executive, Dr. Azam was most recently the Global Head of the Cell & Gene Therapies Unit at Novartis. His previous roles at Novartis included Head of Global Medical Affairs & HEOR General Medicines, Chief Scientific Officer and Head of U.S. Clinical Development & Medical Affairs, and Global Head Regulatory Affairs for the Neurosciences & Ophthalmic Franchise. Before joining Novartis, he was the Chief Executive Officer of Novaccel Therapeutics, a company he founded to accelerate assets in the translational medicine setting. Prior to that he served as Chief Medical Officer at Aspreva Pharmaceutics, a company that focused on orphan and rare autoimmune disease states which was acquired by Galenica in 2008. His earlier career included positions at Johnson & Johnson, Johnson & Johnson Ethicon, and Warner Lambert-Parke Davis. Dr. Azam is a graduate of the University of Liverpool School of Medicine and is board certified in obstetrics and gynecology in the United Kingdom.
- Tmunity Therapeutics, headquartered in Philadelphia, was co-founded in 2015 by the University of Pennsylvania (Penn), the Perelman School of Medicine at Penn and the University of Pennsylvania Health System. The company is focused on unleashing the immunological potential of T cells to treat a wide range of diseases. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), universal engineered T cell platforms, and Chimeric Antigen Receptor (CAR) therapies that exhibit best-in-class control over T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. Tmunity has secured its own manufacturing facility in Norristown, PA, that will enable process improvement and production scale-up to support future multi-center clinical studies across diverse therapeutic indications.
Financial terms:
Latest news:
Is general: Yes
